LS Pharma

Gembloux ·KBO/BCE: BE 0779.459.534

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	13-04-2026	109 d early	2026-00081148
31-12-2024	31-07-2025	17-06-2025	44 d early	2025-00166176
31-12-2023	31-07-2024	07-06-2024	54 d early	2024-00118978
31-12-2022	31-07-2023	28-03-2023	125 d early	2023-00048117

Metric	This company	Sector median	Position in the sector
Solvency	74.1%	13.8%	better than 95% of 242 sector peers
Net result	€65k	€19k	better than 69% of 242 sector peers
Equity	€555k	€94k	better than 82% of 242 sector peers
Gross operating margin	€362k	€319k	better than 56% of 214 sector peers
Staff costs	€244k	€279k	higher than 45% of 214 sector peers

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€749k
Fixed assets	21/28	€82k
Tangible fixed assets	22/27	€82k
Current assets	29/58	€668k
Stocks & contracts in progress	3	€351k
Amounts receivable within one year	40/41	€129k
Cash & bank	54/58	€185k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€749k
Equity	10/15	€555k
Contributions / capital	10/11	€4k
Reserves	13	€243k
Accumulated profits (losses)	14	€309k
Amounts payable	17/49	€194k
Amounts payable within one year	42/48	€189k
Trade debts payable within one year	44	€123k
Income statement
Gross operating margin	9900	€362k
Operating result	9901	€96k
Financial income	75	€1
Financial charges	65	€4k
Result before taxes	9903	€92k
Income taxes	67/77	€27k
Net result for the period	9904	€65k
Result to be appropriated	9905	€65k

Summary